Aktis Oncology, Inc. — Investor Relations & Filings

Aktis Oncology, Inc. is a clinical-stage biotechnology company focused on developing a new class of targeted alpha radiopharmaceuticals to treat cancer. The company aims to expand the breakthrough potential of these therapies to large patient populations, addressing prevalent tumor types historically beyond the reach of conventional radiopharmaceuticals. Aktis utilizes a proprietary miniprotein radioconjugate platform designed to generate tumor-targeting agents with ideal properties for alpha radiotherapy, seeking to safely confer breakthrough efficacy. Its pipeline focuses on precision therapies, with a lead candidate, AKY-1189, currently in a Phase 1b clinical trial for locally advanced or metastatic urothelial carcinoma (mUC).